Compare YDKG & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDKG | XAIR |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | China | United States |
| Employees | 17 | N/A |
| Industry | Advertising | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.4M |
| IPO Year | N/A | 2015 |
| Metric | YDKG | XAIR |
|---|---|---|
| Price | $0.89 | $0.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 138.5K | ★ 204.2K |
| Earning Date | 05-12-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,705,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $0.02 | $0.15 |
| 52 Week High | $3.90 | $3.78 |
| Indicator | YDKG | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 41.33 |
| Support Level | $0.81 | N/A |
| Resistance Level | $1.02 | $0.59 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 24.70 | 31.30 |
Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.